Table 3.
Per-protocol Analysis of the 14 patients who completed the study
| Screening | Drug Initiation | End of drug | |
|---|---|---|---|
| Weight (lb) | 184.3±34.4 | 186.3±35.1 | 177.3±33.6 (p=0.03) |
| Spironolactone dose | 107±111 | 45±103 | 38±50 |
| Furosemide dose | 62±40 | 35±39 | 23±29 |
| Laboratory indices | |||
| Na (meq/L) | 124±3 | 126±2 | 133±4 (p=0.001) |
| K (meq/L) | 4.5±0.7 | 4.4±0.5 | 4.5±0.4 |
| P (meq/L) | 3.1±0,5 | 3.2±0.5 | 3.2±0.7 |
| Mg (meq/L) | 1.9±0.2 | 1.9±0.2 | 1.9±0.4 |
| Ammonia (μmol/L) | 63.3±26.8 | 63.5±24.7 | 44±14* |
| Creatinine (mg/dl) | 1.0±0.3 | 1.0±0.3 | 1.2±0.9 |
| INR | 1.7±0.5 | 1.7±0.5 | 1.9±0.7 |
| AST | 85.4±40.5 | 82.1±45.7 | 73.4±48.9 |
| ALT | 58.6±42.5 | 60.1±44.7 | 54.5±45.9 |
| Albumin (g/dl) | 2.9±0.6 | 2.9±0.7 | 2.8±0.7 |
| Total bilirubin (mg/dl) | 4.2±4.2 | 4.2±3.8 | 5.0±5.6 |
| Hemoglobin(g/dl) | 10.3±1.4 | |10.0±1.3 | 9.8±1.8 |
| WBC count (/mm3) | 6.5±2.9 | 6.1±3.3 | 6.5±3.4 |
| Platelets(/mm3) | 95.6±69.9 | 91.4±72.0 | 97.7±75.2 |
| MELD score | 18±7 | 18±8 | 18±7 |
| Cognitive tests | |||
| Number Connection-A(s) | 59±41 | 64±58 | 48±22 (p=0.02) |
| Number Connection-B(s) | 166±73 | 174±117 | 130±50 (p=0.01) |
| Digit symbol (raw) | 37±15 | 39±15 | 44±18 |
| Block design(raw) | 18±11 | 19±11 | 22±9 |
| Line tracing time (s) | 151 ±61 | 165±127 | 148±102 |
| Line tracing errors (no.) | 54±52 | 55±47 | 45±40 (p=0.001) |
| Serial Dotting (s) | 111±58 | 100±46 | 92±49 |
| ICT lures (no.) | 15±9 | 19±13 | 13±8 (p=0.002) |
| ICT targets (%) | 84±21 | 88±11 | 87±17 |
| Median PHES (range) | −7.0 (−11.0-0.0) | −6.75 (−11.0-0.0) | −2.75 (−9.0-0) |
| % any improvement | - | 0 (0%) | 9 (64%) (p=0.005) |
| Normal cognition | 0 (0%) | 1 (7%) | 7 (50%) (p=0.03) |
All significant p values between drug initiation compared to end-of-drug are in parentheses. None of the comparisons between screening and drug initiation were statistically significant